It is reasonable to conclude that MC2 can decrease the risk of ketoacidosis through inhibition of lipolysis in diabetic patients who are candidate to PDE inhibitor therapy due to cardiovascular diseases. The gene discussed is ALDH7A1; the disease is cardiovascular disorder.